Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18402678 | CHEMOSELECTIVE HYDROGENATION OF a,B-UNSATURATED KETONE AND POLYELECTROCHROMISM OF ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(2-HYDROXYQUINOLATO(PiPr3)2 MOIETIES | January 2024 | June 2024 | Allow | 5 | 0 | 0 | No | No |
| 18148370 | METHOD FOR PREPARING DIARYL P-PHENYLENEDIAMINE COMPOUNDS | December 2022 | April 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 17284549 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | October 2022 | June 2024 | Allow | 38 | 0 | 0 | No | No |
| 17859675 | OXAZOLE COMPOUND CRYSTAL | July 2022 | July 2023 | Allow | 13 | 1 | 0 | No | No |
| 17847935 | COMPOSITIONS AND METHODS RELATING TO INHIBITORS OF PRO-INFLAMMATORY FACTORS FOR TREATMENT OF CANCER | June 2022 | November 2023 | Allow | 16 | 1 | 0 | No | No |
| 17840876 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | June 2022 | November 2023 | Allow | 17 | 1 | 1 | No | No |
| 17824407 | Bicyclic Compounds and their Uses | May 2022 | August 2023 | Allow | 15 | 0 | 1 | No | No |
| 17735273 | RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS | May 2022 | December 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17724212 | GLP-1R MODULATING COMPOUNDS | April 2022 | October 2023 | Allow | 18 | 1 | 1 | No | No |
| 17714962 | PYRIDINYL INDOLE COMPOUNDS AND METHODS OF USE THEREOF | April 2022 | October 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17633163 | NEW TELESCOPING SYNTHESES OF 2-METHOXYMETHYL-P-PHENYLENEDIAMINE | February 2022 | April 2024 | Allow | 27 | 1 | 1 | No | No |
| 17541088 | CANCER THERAPY BY INTRATUMORAL INJECTION OF A CHEMOTHERAPEUTIC AGENT IN COMBINATION WITH A BIOACTIVE IMMUNOSTIMULATORY AGENT | December 2021 | October 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17528434 | NEDOCROMIL SODIUM TO PREVENT, LIMIT ONSET, AND /OR TREAT PANCREATIC CANCER | November 2021 | October 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17610063 | METAL-ORGANIC STRUCTURAL BODY | November 2021 | October 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17608140 | PREPARATION OF SILOXANES IN THE PRESENCE OF CATIONIC GERMANIUM(II) COMPOUNDS | November 2021 | May 2024 | Allow | 31 | 1 | 0 | No | No |
| 17599126 | METAL COMPLEXES FOR GAS-PHASE THIN-FILM DEPOSITION | September 2021 | May 2024 | Allow | 32 | 0 | 1 | No | No |
| 17442450 | NOVEL ORGANOGERMANIUM COMPOUND | September 2021 | January 2024 | Allow | 28 | 0 | 0 | No | No |
| 17433287 | SILYL ETHER-CONTAINING SULFONATE SALT | August 2021 | May 2024 | Allow | 32 | 1 | 0 | No | No |
| 17410635 | COMPOUND, ELECTROLYTIC SOLUTION ADDITIVE, ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | August 2021 | February 2024 | Allow | 30 | 0 | 0 | No | No |
| 17433005 | PHOSPHORESCENT C^C* PLATINUM(II) COMPLEXES WITH BORONIC LIGANDS AND THEIR USE AS EMITTERS IN OLEDS | August 2021 | September 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17310633 | Metal-Organic Framework Materials Comprising A Diimine Bis-Salicylate Scaffold And Methods For Production Thereof | August 2021 | March 2024 | Allow | 31 | 1 | 0 | No | No |
| 17310615 | Production And Use Of Metal Organic Frameworks | August 2021 | September 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17273787 | METHOD FOR PRODUCING DIALKYLAMIDO ELEMENT COMPOUNDS | July 2021 | September 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17419272 | ORGANOMETALLIC CHAIN TRANSFER AGENTS | June 2021 | June 2024 | Allow | 36 | 1 | 0 | No | No |
| 17417418 | Solid-State Synthesis Of Precursors Of Metal-Organic Frameworks | June 2021 | October 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17298956 | PREPARATION METHOD OF RHODIUM OCTANOATE DIMER | June 2021 | March 2024 | Allow | 33 | 1 | 0 | Yes | No |
| 17335145 | COMPOUNDS USEFUL IN HIV THERAPY | June 2021 | October 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17294455 | PROCESS FOR REDUCING THE CONTENT OF BORON COMPOUNDS IN HALOSILANE-CONTAINING COMPOSITIONS | May 2021 | April 2024 | Allow | 35 | 1 | 0 | No | No |
| 17224513 | METHODS FOR VAPOR DEPOSITION OF GROUP 4 TRANSITION METAL-CONTAINING FILMS USING GROUP 4 TRANSITION METAL-CONTAINING FILMS FORMING COMPOSITIONS | April 2021 | June 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17281661 | ORGANOSILICON COMPOUND, METHOD FOR PRODUCING THEREOF, AND USE THEREOF | March 2021 | May 2024 | Allow | 37 | 0 | 1 | No | No |
| 17211352 | CRYSTALLIZATION PROCESS OF ARIPIPRAZOLE DERIVATIVES IN EXTENDED RELEASE FORMULATIONS FOR TREATMENT OF SCHIZOPHRENIA | March 2021 | September 2023 | Allow | 30 | 1 | 0 | No | No |
| 17277700 | AN ORGANOMETALLIC COMPOUND FOR HYDROCARBON CRACKING | March 2021 | April 2024 | Allow | 37 | 1 | 1 | No | No |
| 17273774 | NOVEL HYDROCHLORIDE SALT FORMS OF A SULFONAMIDE STRUCTURED KINASE INHIBITOR | March 2021 | September 2023 | Allow | 30 | 1 | 0 | No | No |
| 17189989 | PRMT5 INHIBITORS AND USES THEREOF | March 2021 | December 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17138884 | METAL TIN CYCLIZED PERYLENE DIIMIDE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND METHOD FOR USING THE SAME | December 2020 | April 2024 | Allow | 39 | 1 | 0 | No | No |
| 17057864 | IONIC METAL ALKYLIDENE COMPOUNDS AND USE THEREOF IN OLEFINIC METATHESIS REACTIONS | November 2020 | June 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17050329 | NEW CRYSTAL FORM OF ACALBRUTINIB, PREPARATION METHOD THEREFOR AND USE THEREOF | October 2020 | August 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17050392 | CDK4/6 INHIBITOR AND PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPH THEREOF AND USE THEREOF | October 2020 | August 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17046402 | Compositions for Preventing or Treating Dry Eye | October 2020 | October 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16957535 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | October 2020 | October 2023 | Abandon | 40 | 0 | 1 | No | No |
| 16978202 | MEMANTINE PAROXETINE COCRYSTAL SALT AND ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION | September 2020 | August 2023 | Allow | 36 | 1 | 0 | No | No |
| 16975906 | ASCORBIC ACID FORMULATION | August 2020 | October 2023 | Allow | 38 | 2 | 0 | No | No |
| 16617409 | NOVEL PHENOXYACETIC ACID DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS MEDICAMENT | November 2019 | October 2023 | Allow | 47 | 6 | 1 | Yes | No |
| 16561515 | CONDUCTIVITY ENHANCEMENT OF MOFS VIA DEVELOPMENT OF MOFPOLYMER COMPOSITE MATERIAL | September 2019 | June 2021 | Abandon | 21 | 1 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner HOU, FRANK S works in Art Unit 1622 and has examined 43 patent applications in our dataset. With an allowance rate of 58.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner HOU, FRANK S's allowance rate of 58.1% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HOU, FRANK S receive 0.86 office actions before reaching final disposition. This places the examiner in the 9% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by HOU, FRANK S is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +45.0% benefit to allowance rate for applications examined by HOU, FRANK S. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 12.5% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 85.7% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 24.0% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.